title: Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
abstract: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) are effective against lung adenocarcinoma. However, limited data is available assessing the effectiveness of EGFR-TKI use in preventing re-accumulation of MPE. To our knowledge, there is no literature on comparison of talc pleurodesis with EGFR-TKIs alone on re-accumulation of MPE in Asian population. We investigated if EGFR-TKI therapy for advanced lung adenocarcinoma with malignant pleural effusion (MPE) is also successful in preventing pleural fluid re-accumulation following initial drainage.
  
  
  
  An observational cohort study of patients with lung adenocarcinoma and MPE in the year 2012 was conducted.
  
  
  
  70 patients presented with MPE from lung adenocarcinoma. Fifty six underwent EGFR mutation testing of which 39 (69.6%) had activating EGFR mutation and 34 (87.1%) received TKI. 20 were managed by pleural fluid drainage only whereas 14 underwent talc pleurodesis following pleural fluid drainage. Time taken for the pleural effusion to re-accumulate in those with and without pleurodesis was 9.9 vs. 11.7 months, p=0.59 respectively. More patients (n=10, 25.6%) with activating EGFR mutation presented with complete opacification (white-out) of the hemithorax compared to none without activating EGFR mutation (p=0.02).
  
  
  
  In TKI eligible patients, early talc pleurodesis may not confer additional benefit in preventing re-accumulation of pleural effusion and may be reserved for non-adenocarcinoma histology, or EGFR negative adenocarcinoma. Complete opacification of the hemithorax on presentation may serve as an early radiographic signal of positive EGFR mutation status.
authors.affiliation: Tan Tock Seng Hospital, Department of Respiratory and Critical Care Medicine, 11 Jalan Tan Tock Seng, Singapore 308433. Verma@ttsh.com.sg.
authors.forename: Akash
authors.initials: A
authors.lastname: Verma
authors.forename: Akhil
authors.initials: A
authors.lastname: Chopra
authors.forename: Yeo W
authors.initials: YW
authors.lastname: Lee
authors.forename: Lavina D
authors.initials: LD
authors.lastname: Bharwani
authors.forename: Atasha B
authors.initials: AB
authors.lastname: Asmat
authors.forename: Dokeu B A
authors.initials: DB
authors.lastname: Aneez
authors.forename: Fazuludeen A
authors.initials: FA
authors.lastname: Akbar
authors.forename: Albert Y H
authors.initials: AY
authors.lastname: Lim
authors.forename: Sanjay H
authors.initials: SH
authors.lastname: Chotirmall
authors.forename: John
authors.initials: J
authors.lastname: Abisheganaden
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000235:genetics / Q000628:therapy*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000235:genetics / Q000517:prevention & control; D016066:Pleural Effusion, Malignant / Q000000981:diagnostic imaging / Q000235:genetics / Q000628:therapy*; D018700:Pleurodesis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011859:Radiography; D013627:Talc / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D013627:Talc; D066246:ErbB Receptors